Search Result

All Related Services Other Content

Improving the Manufacture of mRNA Biologics
Applying PBPK and PBBM Across R&D: From Early Insights to Formulation Presented by: Deanna Mudie, Ph.D. Senior Principal Scientist of PBPK R&D Simulations Plus
Mol2Med™ Developability Assessment: Material-Sparing, Rapid Studies, and Developability Strategies From early developability to late-stage specifications—polymorph/salt-cocrystal strategy, SCXRD/MicroED solutions, solvent & pathway design, drug-product form control, ASD crystalline-form limits...
Technical Insight
Meet Crystal Pharmatech at DCAT Week 2026 Crystal Pharmatech is returning to DCAT Week with expanded capabilities. We have grown into a global CDMO with 300+ scientists across the US, Canada, and China, having supported over 2,000 NCEs to dat...
Crystal Pharmatech Viewpoint: Analysis of Polymorph Patent Strategies for Small Molecule New Drugs Approved by the FDA in 2025
Predicting Physical Stability of Amorphous Solid Dispersions (ASD)
Conquering the “Uncrystallizable”: Advanced Strategies for PROTAC Solid-Form Development In the world of drug development, PROTACs (Proteolysis Targeting Chimeras) are notoriously difficult to crystallize. Their high molecular weight, inherent flexibility, and complex surface area often l...
Single Crystal Growth & Structure Determination Single crystal growth and structure determination technology are the main methods to determine the absolute configuration of drug molecules and identify the crystal forms absolutely. The single crysta...
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides With the ever-increasing demand for the absorbability of small-molecule oral innovative drugs, more and more new molecules have hydrophobic properties, resulting in very low solubility. According to the latest statistics, about 70% of the small-molecule drugs under research are insoluble substances of BCS II or IV.
Our People
Events
Case Study 3: Atorvastatin - Crystalline Form Change In Late Development Atorvastatin (CI-981) is an HMG CoA reductase inhibitor marketed as Lipitor® (Fig. 8). As a BCS II drug, it has exhibited poor solubility and high permeability (Wu and Benet 2005). The compound was o...
Selecting the Right API Form and Formulation Selecting the Right API Form and Formulation